Is 50 mg/day the new standard dose of dasatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase?

被引：1
|
作者：
Saydan, Betuel [1 ]
Ozmen, Deniz [2 ]
Eskazan, Ahmet Emre [2 ]
机构：
[1] Ankara Univ, Fac Med, Ankara, Turkiye
[2] Istanbul Univ Cerrahpasa, Cerrahpasa Fac Med, Dept Internal Med, Div Hematol, Istanbul, Turkiye
来源：
EXPERT REVIEW OF HEMATOLOGY | 2024年 / 17卷 / 07期
关键词：
Chronic myeloid leukemia; CML; dasatinib; low-dose; 50; mg; CHRONIC LYMPHOCYTIC-LEUKEMIA; DECISION-SUPPORT-SYSTEM; SURVIVAL; CLL; INCORPORATE; PREFERENCES; POPULATION; GUIDELINES; IBRUTINIB; LYMPHOMA;
D O I：
10.1080/17474086.2024.2370556
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：275 / 277
页数：3
相关论文
共 50 条
  • [41] Asciminib in Newly Diagnosed Chronic Myeloid Leukemia
    Hochhaus, Andreas
    Wang, Jianxiang
    Kim, Dong-Wook
    Kim, Dennis Dong Hwan
    Mayer, Jiri
    Goh, Yeow-Tee
    le Coutre, Philipp
    Takahashi, Naoto
    Kim, Inho
    Etienne, Gabriel
    Andorsky, David
    Issa, Ghayas C.
    Larson, Richard A.
    Bombaci, Felice
    Kapoor, Shruti
    McCulloch, Tracey
    Malek, Kamel
    Yau, Lillian
    Ifrah, Sophie
    Hoch, Matthias
    Cortes, Jorge E.
    Hughes, Timothy P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (10) : 885 - 898
  • [42] Performance of Sokal and Eutos Scores for Predicting Cytogenetic and Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia-Chronic Phase Patients on Imatinib
    Ganguly, Sandip
    Lakshmaiah, K. C.
    Jacob, Linu Abraham
    Babu, Suresh
    Dasappa, Lokanatha
    Babu, K. S. Govind
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2017, 33 (01) : 82 - 86
  • [43] Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia
    Ota, Shuichi
    Matsukawa, Toshihiro
    Yamamoto, Satoshi
    Ito, Shinichi
    Shindo, Motohiro
    Sato, Kazuya
    Kondo, Takeshi
    Kohda, Kyuhei
    Sakai, Hajime
    Mori, Akio
    Takahashi, Tohru
    Ikeda, Hiroshi
    Kuroda, Hiroyuki
    Haseyama, Yoshihito
    Yamamoto, Masaki
    Sarashina, Takeo
    Yoshida, Makoto
    Kobayashi, Ryoji
    Nishio, Mitsufumi
    Ishihara, Toshimichi
    Hirayama, Yasuo
    Kakinoki, Yasutaka
    Kobayashi, Hajime
    Fukuhara, Takashi
    Imamura, Masahiro
    Kurosawa, Mitsutoshi
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 101 (01) : 95 - 105
  • [44] Dose escalation of imatinib in chronic-phase chronic myeloid leukemia patients: is it still reasonable?
    Rudzki, Jakob
    Wolf, Dominik
    EXPERT REVIEW OF HEMATOLOGY, 2011, 4 (02) : 153 - 159
  • [45] Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily
    Krauth, Maria-Theresa
    Herndlhofer, Susanne
    Schmook, Maria-Theresa
    Mitterbauer-Hohendanner, Gerlinde
    Schloegl, Ernst
    Valent, Peter
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (01): : 163 - 166
  • [46] Association of pleural effusion with an early molecular response. in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study
    Hagihara, Maki
    Iriyama, Noriyoshi
    Yoshida, Chikashi
    Wakita, Hisashi
    Chiba, Shigeru
    Okamoto, Shinichiro
    Kawakami, Kimihiro
    Takezako, Naoki
    Kumagai, Takashi
    Inokuchi, Koiti
    Ohyashiki, Kazuma
    Taguchi, Jun
    Yano, Shingo
    Igarashi, Tadahiko
    Kouzai, Yasuji
    Morita, Satoshi
    Sakamoto, Junichi
    Sakamaki, Hisashi
    ONCOLOGY REPORTS, 2016, 36 (05) : 2976 - 2982
  • [47] High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients-Systematic review and meta-analysis
    Gafter-Gvili, Anat
    Leader, Avi
    Gurion, Ronit
    Vidal, Liat
    Ram, Ron
    Shacham-Abulafia, Adi
    Ben-Bassat, Isaac
    Lishner, Michael
    Shpilberg, Ofer
    Raanani, Pia
    AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (08) : 657 - 662
  • [48] Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the chronic phase
    孔军
    ChinaMedicalAbstracts(InternalMedicine), 2017, 34 (01) : 53 - 54
  • [49] Evaluation of Medication Adherence and Pharmacokinetics of Dasatinib for Earlier Molecular Response in Japanese Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Pilot Study
    Iwamoto, Takuya
    Monma, Fumihiko
    Ohishi, Kohshi
    Umino, Akira
    Suzuki, Kei
    Oka, Koji
    Kawakami, Keiki
    Sekine, Takao
    Okuda, Masahiro
    Katayama, Naoyuki
    THERAPEUTIC DRUG MONITORING, 2019, 41 (05) : 575 - 581
  • [50] Dose optimisation of ponatinib in chronic phase chronic myeloid leukemia
    Huguet, Francoise
    Rea, Delphine
    Cayssials, Emilie
    Etienne, Gabriel
    Nicolini, Franck-Emmanuel
    EXPERT REVIEW OF HEMATOLOGY, 2023,
12345